{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:34:32Z","timestamp":1773290072955,"version":"3.50.1"},"reference-count":45,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.3892\/or.2013.2561","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T07:13:03Z","timestamp":1371798783000},"page":"1497-1505","source":"Crossref","is-referenced-by-count":16,"title":["Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells"],"prefix":"10.3892","volume":"30","author":[{"given":"KUN-HUANG","family":"YAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LIANG-MING","family":"LEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAO-CHIH","family":"HSIEH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MING-DE","family":"YAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHIH-JUNG","family":"YAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PEY-YI","family":"CHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TSUNG-LI","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HWAN-YOU","family":"CHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANN-LII","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GI-MING","family":"LAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHUANG-EN","family":"CHUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,6,21]]},"reference":[{"key":"key20180107223127_b1-or-30-03-1497","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10428190701824569","article-title":"Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells","volume":"49","author":"Fotoohi","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"key20180107223127_b2-or-30-03-1497","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/rheumatology\/kem147","article-title":"The pharmacogenetics of methotrexate","volume":"46","author":"Hider","year":"2007","journal-title":"Rheumatology"},{"key":"key20180107223127_b3-or-30-03-1497","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1254\/jphs.FP0050761","article-title":"Cell-cycle-dependent pharmacology of methotrexate in HL-60","volume":"99","author":"Yamauchi","year":"2005","journal-title":"J Pharmacol Sci"},{"key":"key20180107223127_b4-or-30-03-1497","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol Rev"},{"key":"key20180107223127_b5-or-30-03-1497","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"key20180107223127_b6-or-30-03-1497","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"key20180107223127_b7-or-30-03-1497","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res"},{"key":"key20180107223127_b8-or-30-03-1497","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20180107223127_b9-or-30-03-1497","first-page":"548","article-title":"Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease","volume":"10","author":"Hani","year":"2000","journal-title":"Eur J Dermatol"},{"key":"key20180107223127_b10-or-30-03-1497","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1593\/neo.04169","article-title":"Chemotherapy-induced and\/or radiation therapy-induced oral mucositis - complicating the treatment of cancer","volume":"6","author":"Naidu","year":"2004","journal-title":"Neoplasia"},{"key":"key20180107223127_b11-or-30-03-1497","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10585-005-5377-y","article-title":"Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma","volume":"22","author":"Tomoda","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"key20180107223127_b12-or-30-03-1497","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0190-9622(82)70005-2","article-title":"Combined methotrexate-PUVA therapy in the treatment of psoriasis","volume":"6","author":"Morison","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"key20180107223127_b13-or-30-03-1497","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/1078-0432.CCR-05-1834","article-title":"Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer","volume":"12","author":"Sweeney","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107223127_b14-or-30-03-1497","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1002\/art.10505","article-title":"Aspirin antiplatelet therapy and nonsteroidal antiinflammatory drugs: comment on the 2002 update of the American College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis","volume":"46","author":"Pablos","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20180107223127_b15-or-30-03-1497","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2407-2-31","article-title":"Regular aspirin use and lung cancer risk","volume":"2","author":"Moysich","year":"2002","journal-title":"BMC Cancer"},{"key":"key20180107223127_b16-or-30-03-1497","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/1055-9965.EPI-07-0517","article-title":"Regular adult aspirin use decreases the risk of non-small cell lung cancer among women","volume":"17","author":"Van Dyke","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180107223127_b17-or-30-03-1497","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180107223127_b18-or-30-03-1497","first-page":"2072","article-title":"The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg","volume":"22","author":"Kremer","year":"1995","journal-title":"J Rheumatol"},{"key":"key20180107223127_b19-or-30-03-1497","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/art.1780341207","article-title":"Aspirin alters methotrexate disposition in rheumatoid arthritis patients","volume":"34","author":"Stewart","year":"1991","journal-title":"Arthritis Rheum"},{"key":"key20180107223127_b20-or-30-03-1497","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.1780331102","article-title":"Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis","volume":"33","author":"Fries","year":"1990","journal-title":"Arthritis Rheum"},{"key":"key20180107223127_b21-or-30-03-1497","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1165\/ajrcmb.17.3.2837","article-title":"Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line","volume":"17","author":"Chu","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"key20180107223127_b22-or-30-03-1497","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0277-5379(91)90142-Z","article-title":"Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing","volume":"27","author":"Keepers","year":"1991","journal-title":"Eur J Cancer"},{"key":"key20180107223127_b23-or-30-03-1497","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"key20180107223127_b24-or-30-03-1497","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"key20180107223127_b25-or-30-03-1497","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mc.20593","article-title":"The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells","volume":"49","author":"Yan","year":"2010","journal-title":"Mol Carcinog"},{"key":"key20180107223127_b26-or-30-03-1497","first-page":"1297","article-title":"Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate","volume":"20","author":"Rooney","year":"1993","journal-title":"J Rheumatol"},{"key":"key20180107223127_b27-or-30-03-1497","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11926-004-0009-0","article-title":"Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis","volume":"6","author":"Kurth","year":"2004","journal-title":"Curr Rheumatol Rep"},{"key":"key20180107223127_b28-or-30-03-1497","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/14622416.9.4.439","article-title":"An update on methotrexate pharmacogenetics in rheumatoid arthritis","volume":"9","author":"Ranganathan","year":"2008","journal-title":"Pharmacogenomics"},{"key":"key20180107223127_b29-or-30-03-1497","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14622416.5.7.819","article-title":"Pharmacogenetics of methotrexate","volume":"5","author":"Krajinovic","year":"2004","journal-title":"Pharmacogenomics"},{"key":"key20180107223127_b30-or-30-03-1497","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/mc.20318","article-title":"Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition","volume":"46","author":"Bock","year":"2007","journal-title":"Mol Carcinog"},{"key":"key20180107223127_b31-or-30-03-1497","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejphar.2006.04.030","article-title":"Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment","volume":"540","author":"Janssen","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"key20180107223127_b32-or-30-03-1497","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1128\/MCB.15.8.4347","article-title":"Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1","volume":"15","author":"Resnitzky","year":"1995","journal-title":"Mol Cell Biol"},{"key":"key20180107223127_b33-or-30-03-1497","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/onc.2009.127","article-title":"Degradation of cyclin A is regulated by acetylation","volume":"28","author":"Mateo","year":"2009","journal-title":"Oncogene"},{"key":"key20180107223127_b34-or-30-03-1497","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.bcp.2008.06.023","article-title":"Regulation of CD95\/APO-1\/Fas-induced apoptosis by protein phosphatases","volume":"76","author":"Gloire","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"key20180107223127_b35-or-30-03-1497","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drup.2006.04.002","article-title":"Fas\/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy","volume":"9","author":"Mollinedo","year":"2006","journal-title":"Drug Resist Updat"},{"key":"key20180107223127_b36-or-30-03-1497","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/cncr.20270","article-title":"The role of Fas ligand and transforming growth factor \u03b2 in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy","volume":"100","author":"Kim","year":"2004","journal-title":"Cancer"},{"key":"key20180107223127_b37-or-30-03-1497","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1517\/14728222.9.5.1031","article-title":"Targeting the Fas\/Fas ligand pathway in cancer","volume":"9","author":"O\u2019Brien","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"key20180107223127_b38-or-30-03-1497","first-page":"535","article-title":"mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma","volume":"2","author":"Sowers","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"key20180107223127_b39-or-30-03-1497","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/MCB.13.3.1610","article-title":"A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter","volume":"13","author":"Slansky","year":"1993","journal-title":"Mol Cell Biol"},{"key":"key20180107223127_b40-or-30-03-1497","doi-asserted-by":"crossref","first-page":"22721","DOI":"10.1074\/jbc.M500277200","article-title":"Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment","volume":"280","author":"Skacel","year":"2005","journal-title":"J Biol Chem"},{"key":"key20180107223127_b41-or-30-03-1497","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.0706217104","article-title":"A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance","volume":"104","author":"Mishra","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107223127_b42-or-30-03-1497","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/gcc.20509","article-title":"Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability","volume":"47","author":"Snijders","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180107223127_b43-or-30-03-1497","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/stem.140005","article-title":"Resistance mechanisms to methotrexate in tumors","volume":"14","author":"Bertino","year":"1996","journal-title":"Stem Cells"},{"key":"key20180107223127_b44-or-30-03-1497","doi-asserted-by":"crossref","first-page":"12317","DOI":"10.1021\/bi971026e","article-title":"Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region","volume":"36","author":"Ercikan-Abali","year":"1997","journal-title":"Biochemistry"},{"key":"key20180107223127_b45-or-30-03-1497","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/mol.109.055772","article-title":"Species-specific differences in translational regulation of dihydrofolate reductase","volume":"76","author":"Hsieh","year":"2009","journal-title":"Mol Pharmacol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2561\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T22:10:04Z","timestamp":1595974204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,21]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,6,21]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.3892\/or.2013.2561"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2561","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,21]]}}}